{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:07:17Z","timestamp":1761962837285,"version":"build-2065373602"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipoprotein(a) is a low-density lipoprotein-like particle covalently bound to apolipoprotein(a). It exhibits pro-atherogenic and pro-inflammatory effects and is an established independent monogenic determinant of atherosclerotic cardiovascular disease and aortic valve stenosis [1\u20134].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To establish the Lp(a) distribution in a native Irish population and to explore if a certain lipid profile was associated with high Lp(a) level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively included all subjects with Lp(a) results tested in our laboratory between January 2021 and December 2022. Patients were divided into Irish and non-Irish name subgroups [16]. We analysed the Lp(a) distribution across lipidaemic subgroups. Statistical analyses were completed in Jamovi programme V2.3.26.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total 2762 patients of which 1899 had also a lipid profile. Eighty-five percent (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092359) of individuals had Irish surnames and 60% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091419) were males. Mean age of all patients was 56\u2009\u00b1\u200917\u00a0years. The median lipoprotein(a) level was 34.5\u00a0nmol\/L (interquartile interval\u2009&lt;\u200920 to 153). The Lp(a) median in females was 37.3 (interquartile interval\u2009&lt;\u200920 to 169) versus males 32.9 (interquartile interval\u2009&lt;\u200920 to 147) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029). A total of 62.9% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091738) of Irish subjects had Lp(a) levels\u2009&lt;\u200975\u00a0nmol\/L, 7.56% of them (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009209) between 75 and 125\u00a0nmol\/L and 29.5% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009815) of subjects had Lp(a)\u2009&gt;\u2009125\u00a0nmol\/L.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the largest study of Lp(a) distribution in an Irish population revealing positively skewed Lp(a) serum levels. This is not entirely reflective of the general population but brings to the fore the additional hidden high risks in those patients attending cardiovascular services. More education is needed to increase the use of Lp(a) measurements and guide further therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11845-025-04003-5","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T07:32:44Z","timestamp":1754724764000},"page":"1567-1572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a) levels in Irish subjects from a specialised lipid centre"],"prefix":"10.1007","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3342-3600","authenticated-orcid":false,"given":"Iulia","family":"Tustiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6493-0517","authenticated-orcid":false,"given":"Dilara","family":"Ensar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailish","family":"O\u2019Keeffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eoin","family":"Begley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Boran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6698-8109","authenticated-orcid":false,"given":"Richard","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-4508","authenticated-orcid":false,"given":"Vincent","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"4003_CR1","doi-asserted-by":"publisher","unstructured":"Maranh\u00e3o RC, Carvalho PO, Strunz CC et al (2014) Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol [Internet] 103(1):76-84. https:\/\/doi.org\/10.5935\/abc.20140101","DOI":"10.5935\/abc.20140101"},{"key":"4003_CR2","doi-asserted-by":"crossref","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L et al (2022) Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol [Internet] 42(1):e48\u2013e60. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34647487\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1161\/ATV.0000000000000147"},{"key":"4003_CR3","doi-asserted-by":"crossref","unstructured":"Kronenberg F, Utermann G (2013) Lipoprotein(a): resurrected by genetics. J Intern Med [Internet] 273(1):6\u201330. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22998429\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1111\/j.1365-2796.2012.02592.x"},{"key":"4003_CR4","doi-asserted-by":"crossref","unstructured":"Pantelidis P, Oikonomou E, Lampsas S et al (2023) Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis. Cardiovasc Res [Internet] 119(8):1641\u20131655. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37078819\/. Accessed 1\/2\/2024","DOI":"10.1093\/cvr\/cvad062"},{"key":"4003_CR5","doi-asserted-by":"crossref","unstructured":"Enkhmaa B, Anuurad E, Berglund L (2016) Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res [Internet] 57(7):1111\u20131125. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26637279\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1194\/jlr.R051904"},{"key":"4003_CR6","doi-asserted-by":"crossref","unstructured":"Par\u00e9 G, \u00c7aku A, McQueen M et al (2019) Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation [Internet] 139(12):1472\u20131482. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30667276\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1161\/CIRCULATIONAHA.118.034311"},{"key":"4003_CR7","doi-asserted-by":"crossref","unstructured":"Nordestgaard BG, Chapman MJ, Ray K et al (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J [Internet] 31(23):2844\u20132853. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20965889\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1093\/eurheartj\/ehq386"},{"key":"4003_CR8","doi-asserted-by":"crossref","unstructured":"Kronenberg F, Mora S, Stroes ESG et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J [Internet] 43(39):3925\u20133946. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36036785\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"4003_CR9","doi-asserted-by":"crossref","unstructured":"Maher VMG, Greg Brown B, Marcovina SM et al (1995) Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA [Internet] 274(22):1771\u20131774. Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/392609.\u00a0Accessed 1\/2\/2024","DOI":"10.1001\/jama.1995.03530220037029"},{"key":"4003_CR10","doi-asserted-by":"crossref","unstructured":"Thompson GR, Maher VMG, Kitano Y et al (1995) Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet [Internet] 345(8953):811\u2013816. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7898227\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1016\/S0140-6736(95)92961-4"},{"key":"4003_CR11","doi-asserted-by":"crossref","unstructured":"Kronenberg F, Mora S, Stroes ESG et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J [Internet] 43(39):3925\u20133946. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36036785\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"4003_CR12","doi-asserted-by":"crossref","unstructured":"Afshar M, Rong J, Zhan Y et al (2020) Risks of incident cardiovascular disease associated with concomitant elevations in lipoprotein(a) and low-density lipoprotein cholesterol-the Framingham Heart Study. J Am Heart Assoc [Internet] 9(18). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32892691\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1161\/JAHA.119.014711"},{"issue":"6","key":"4003_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1155\/2013\/472845","volume":"35","author":"A Cai","year":"2013","unstructured":"Cai A, Li L, Zhang Y and others (2013) Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement. Dis Markers 35(6):857\u2013862","journal-title":"Dis Markers"},{"key":"4003_CR14","doi-asserted-by":"crossref","unstructured":"Zhu L, Zheng J, Gao B et al (2022) The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels. BMC Cardiovasc Disord [Internet] 22(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35428179\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1186\/s12872-022-02618-5"},{"key":"4003_CR15","doi-asserted-by":"crossref","unstructured":"Mach F, Baigent C, Catapano AL et al (2019) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis [Internet] 290:140\u2013205. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31591002\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1016\/j.atherosclerosis.2019.08.014"},{"key":"4003_CR16","doi-asserted-by":"publisher","unstructured":"Kandt J, Longley PA (2018) Ethnicity estimation using family naming practices PLoS ONE 13(8).\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0201774#sec020","DOI":"10.1371\/journal.pone.0201774#sec020"},{"key":"4003_CR17","doi-asserted-by":"crossref","unstructured":"Simony SB, Mortensen MB, Langsted A (2022) Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the copenhagen general population study. atherosclerosis [Internet] 355:76\u201382. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35803767\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1016\/j.atherosclerosis.2022.06.1023"},{"key":"4003_CR18","doi-asserted-by":"crossref","unstructured":"Langsted A, Nordestgaard BG, Kamstrup PR (2021) Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. Eur Heart J [Internet] 42(12):1147\u20131156. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33724357\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1093\/eurheartj\/ehaa1085"},{"key":"4003_CR19","doi-asserted-by":"crossref","unstructured":"Welsh P, Welsh C, Celis-Morales CA et al (2021) Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions.\u00a0Eur J Prev Cardiol\u00a028(18):1991\u20132000. Available from: https:\/\/academic.oup.com\/eurjpc\/article\/28\/18\/1991\/5918819.\u00a0Accessed 1\/2\/2024","DOI":"10.1093\/eurjpc\/zwaa063"},{"key":"4003_CR20","doi-asserted-by":"publisher","unstructured":"Ding L, Song A, Dai M et al (2015) Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population. J Lipid Res [Internet] 56(4):920\u2013926. https:\/\/doi.org\/10.1194\/jlr.P049015","DOI":"10.1194\/jlr.P049015"},{"key":"4003_CR21","doi-asserted-by":"crossref","unstructured":"Maher V, Gallagher J, Agar R et al (2023) Abbreviated lipid guidelines for clinical practice\u202f: based on ESC lipid guidelines 2019 and ESC cardiovascular disease prevention in clinical practice guidelines 2021. Ir J Med Sci [Internet] 192(5):2151\u20132157. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36746882\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1007\/s11845-023-03277-x"},{"key":"4003_CR22","doi-asserted-by":"crossref","unstructured":"Offiah G, O\u2019Connor C, Kennedy C et al (2023) The DA VINCI study: is Ireland achieving ESC\/EAS guideline\u2013directed LDL-C goals? Ir J Med Sci 192(3):1077\u20131084","DOI":"10.1007\/s11845-022-03050-6"},{"key":"4003_CR23","doi-asserted-by":"crossref","unstructured":"Dunne M, Mac Ananey O, Markham C et al (2013) Lipid targets in clinical practice: successes, failures and lessons to be learned. Ir J Med Sci [Internet] 182(4):673\u2013678. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23616070\/.\u00a0Accessed 1\/2\/2024","DOI":"10.1007\/s11845-013-0954-6"},{"key":"4003_CR24","doi-asserted-by":"crossref","unstructured":"Tsimikas S, Gordts PLSM, Nora C et al (2020) Statin therapy increases lipoprotein(a) levels.\u00a0Eur Heart J\u00a041(24):2275\u20132284. Available from: https:\/\/academic.oup.com\/eurheartj\/article\/41\/24\/2275\/5492355.\u00a0Accessed 1\/2\/2024","DOI":"10.1093\/eurheartj\/ehz310"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04003-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-04003-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04003-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:01:31Z","timestamp":1761962491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-04003-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4003"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-04003-5","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For retrospective studies, ethics approval is not required in our institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}